{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:44:33Z","timestamp":1788327873193,"version":"build-2803163510"},"reference-count":23,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007883","name":"Stichting Coolsingel","doi-asserted-by":"publisher","award":["Stichting Coolsingel, Rotterdam, the Netherlands."],"award-info":[{"award-number":["Stichting Coolsingel, Rotterdam, the Netherlands."]}],"id":[{"id":"10.13039\/501100007883","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Chemotherapy-induced alopecia (CIA), a side effect with high impact, can be prevented by cooling the scalp during the administration of some cytotoxic drugs. However, the effects of this prolonged scalp cooling on the pharmacokinetics of chemotherapy have never been investigated. In this study, we compared the pharmacokinetics of the widely used chemotherapeutic agent paclitaxel (weekly dose of 80\u2013100 mg\/m2) in female patients with solid tumors using concomitant scalp cooling (n = 14) or not (n = 24). Blood samples were collected in all patients for pharmacokinetic analyses up to 6 h after one course of paclitaxel administration. The primary endpoint was the clearance (L\/h) of paclitaxel. Paclitaxel clearance\u2014expressed as relative difference in geometric means\u2014was 6.8% (90% CI: \u221216.7% to 4.4%) lower when paclitaxel was administered with concomitant scalp cooling versus paclitaxel infusions without scalp cooling. Within the subgroup of patients using scalp cooling, paclitaxel clearance was not statistically significantly different between patients with CIA (alopecia grade 1 or 2) and those without CIA. Hence, scalp cooling did not negatively influence the clearance of paclitaxel treatment.<\/jats:p>","DOI":"10.3390\/cancers13153915","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T08:16:39Z","timestamp":1627978599000},"page":"3915","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2494-4482","authenticated-orcid":false,"given":"Leni","family":"van Doorn","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-273X","authenticated-orcid":false,"given":"Mandy M.","family":"van Rosmalen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy M.","family":"van der Deure","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Groene Hart Hospital, 2803 HH Gouda, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2506-3852","authenticated-orcid":false,"given":"Esther","family":"Oomen-de Hoop","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Porrazzo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie M.","family":"Wijngaard","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4857-6346","authenticated-orcid":false,"given":"Ingrid A.","family":"Boere","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Veenstra","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Uppsala University, 751 24 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"de Bruijn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena E.","family":"Friberg","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Uppsala University, 751 24 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn L. W.","family":"Koolen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-5697","authenticated-orcid":false,"given":"Ron H. J.","family":"Mathijssen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Jager","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1634\/theoncologist.2017-0263","article-title":"A clinical and biological guide for understanding chemotherapy-induced alopecia and its prevention","volume":"23","author":"Dunnill","year":"2018","journal-title":"Oncologist"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/pon.1615","article-title":"Impact of alopecia and scalp cooling on the well-being of breast cancer patients","volume":"19","author":"Mols","year":"2010","journal-title":"Psychooncology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ejon.2013.02.004","article-title":"Impact of scalp cooling on chemotherapy-induced alopecia, wig use and hair growth of patients with cancer","volume":"17","author":"Breed","year":"2013","journal-title":"Eur. J. Oncol. Nurs."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejon.2003.10.006","article-title":"A multicentre study to determine the efficacy and patient acceptability of the paxman scalp cooler to prevent hair loss in patients receiving chemotherapy","volume":"8","author":"Massey","year":"2004","journal-title":"Eur. J. Oncol. Nurs."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","article-title":"Prevention and management of dermatological toxicities related to anticancer agents: Esmo clinical practice guidelines","volume":"32","author":"Lacouture","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1586\/edm.10.76","article-title":"Presentation, impact and prevention of chemotherapy-induced hair loss","volume":"6","author":"Breed","year":"2011","journal-title":"Expert Rev. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/11319360-000000000-00000","article-title":"Effects of hypothermia on pharmacokinetics and pharmacodynamics: A systematic review of preclinical and clinical studies","volume":"49","author":"Groenendaal","year":"2010","journal-title":"Clin. Pharm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/jps.10161","article-title":"Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model","volume":"91","author":"Gustafson","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"ref_9","unstructured":"Janssen, F.E.M. (2007). Modelling Physiological and Biochemical Aspects of Scalp Cooling. [Ph.D. Thesis, Technical University Eindhoven]."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3109\/0284186X.2012.658966","article-title":"Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients\u2014Results of the dutch scalp cooling registry","volume":"51","author":"Peerbooms","year":"2012","journal-title":"Acta Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1634\/theoncologist.2012-0332","article-title":"Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia","volume":"18","author":"Komen","year":"2013","journal-title":"Oncologist"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40262-017-0563-z","article-title":"Clinical pharmacokinetics of paclitaxel monotherapy: An updated literature review","volume":"57","author":"Stage","year":"2018","journal-title":"Clin. Pharm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"Hulshof","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3109\/02656736.2012.674622","article-title":"Neoadjuvant chemotherapy followed by radiotherapy and concurrent hyperthermia in patients with advanced-stage cervical cancer: A retrospective study","volume":"28","author":"Heijkoop","year":"2012","journal-title":"Int J. Hyperth."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jama.2016.20939","article-title":"Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: The scalp randomized clinical trial","volume":"317","author":"Nangia","year":"2017","journal-title":"JAMA"},{"key":"ref_16","unstructured":"Paxman Coolers ltd (2012, September 09). Paxman psc-2 Brochure. Available online: Http:\/\/ebookbrowse.Com\/psc2-manual-pdf-d234169346."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0959-8049(03)00126-6","article-title":"Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients","volume":"39","author":"Henningsson","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1158\/1078-0432.CCR-12-3786","article-title":"Cyp3a4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity","volume":"19","author":"Elens","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/psp4.12404","article-title":"Nonmem tutorial part i: Description of commands and options, with simple examples of population analysis","volume":"8","author":"Bauer","year":"2019","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"ref_20","unstructured":"US Department of Health and Human Services (2010). Common Terminology Criteria for Adverse Events (Ctcae) Version 4.03."},{"key":"ref_21","unstructured":"European Medicines Agency (2021, August 02). Guideline on the Investigation of Bioequivalence, 20 January 2010, Available online: https:\/\/www.Ema.Europa.Eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.Pdf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1124\/dmd.109.031377","article-title":"Mild hypothermia alters midazolam pharmacokinetics in normal healthy volunteers","volume":"38","author":"Hostler","year":"2010","journal-title":"Drug Metab Dispos."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1038\/psp.2012.4","article-title":"Basic concepts in population modeling, simulation, and model-based drug development","volume":"1","author":"Mould","year":"2012","journal-title":"CPT Pharmacomet. Syst. Pharm."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/15\/3915\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:39:40Z","timestamp":1760164780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/15\/3915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,3]]},"references-count":23,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["cancers13153915"],"URL":"https:\/\/doi.org\/10.3390\/cancers13153915","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,3]]}}}